ශී ලංකා පුජාතාන්තික සමාජවාදී ජනරජයේ ගැසට් පතුය සි විශෝ විය The Gazette of the Democratic Socialist Republic of Sri Lanka

අංක 1913/7 - 2015 මැයි මස 05 වැනි අඟහරුවාදා - 2015.05.05 No. 1913/7 - TUESDAY, MAY 05, 2015

(Published by Authority)

PART I : SECTION (I) — GENERAL

Government Notifications

CONVENSION AGAINST DOPING IN SPORT ACT, No. 33 OF 2013

REGULATIONS made by the Minister of Sports under Section 34 read with Section 3 of the Convention against Doping in Sport Act, No. 33 of 2013.

NAVIN DISSANAYAKE, Minister of Tourism and Sports.

Colombo, 29th April, 2015.

Regulations

1. These regulations may be cited as the Anti-Doping (Prohibited List) Regulations No. 01 of 2015.

2. These regulations shall be deemed to have come into operation on January 1st, 2015.

THE WORLD ANTI-DOPING CODE

The 2015 Prohibited List International Standard

The Official text of the **Prohibited List** shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail.

This List shall come into effect on 01st January 2015.

The 2015 prohibited List 20th September 2014



This Gazette Extraordinary can be downloaded from www.documents.gov.lk

THE 2015 PROHIBITED LIST WORLD ANTI-DOPING CODE

Valid 01st January 2015

IN accordance with Article 4.2.2 of the World Anti-Doping Code, all Prohibited Substances shall be considered as "Specified Substances" except Substances in classes S1, S2, S4.4, S4.5, S6.a, and Prohibited Methods M1, M2 and M3.

SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN-AND OUT-OF-COMPETITION)

PROHIBITED SUBSTANCES

SO. NON-APPROVED SUBSTANCES

Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or cinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times.

S1. ANABOLIC AGENTS

Anabolic agents are prohibited.

1. Anabolic Androgenic Steroids (AAS)

a. Exogenous* AAS including:

1- androstenediol (5α -androst-1-ene- 3β ,17 β -diol); **1-androstenedione** (5α -androst-1-ene-3, 17-dione); **bolandiol** (estr-4-ene- 3β ,17 β -diol); **bolasterone; boldenone; boldione** (androsta-1,4-diene-3,17-dione); calusterone; clostebol; danazol ([1,2]oxazolo[4',5':2,3]pregna-4-en-20-yn-17 α -ol); **dehydrochlormethyltestosterone** (4-chloro-17 β -hydroxy-17 α -methylandrosta-1,4-dien-3-one); desoxymethyltestosterone (17 α -methyl-5 α -androst-2,-en-17 β -ol); drostanolone; ethylestrenol (19-norpregna-4-en-17 α -ol); fluoxymesterone; formebolone; furazabol (17 α -methyl[1,2,5]oxadiozolo[3',4':2,3]-5 α -androstan-17 β -ol); gestrionone; 4-hydroxytestosterone (4,17 β -dihydroxyandrost-4-en-3-one); mestanolone, mestarolone, metandienone; (17 β -hydroxy-17 α -methylandrosta-1,4-dien-3-one); methylandrosta-1,4-dien-3-one); methylandrosta-1,4-dien-3-one); methylorexy-17 α -methylestra-4,9-dien-3-one); Methyl-1-testosterone (17 β -hydroxy-17 α -methyl-5 α -androstan-3-one); methylorexy-17 α -methylestra-4,9-dien-3-one); Methyl-1-testosterone (17 β -hydroxy-17 α -methyl-5 α -androstan-3-one); methylnortestosterone (17 β -hydroxy-17 α -methylestra-4,9-dien-3-one); methylnortestosterone (17 β -hydroxy-17 α -methylestra-4,9,11-trien-3-one); methylnortestosterone (17 β -hydroxy-17 α -methylestra-4,9,11-trien-3-one); methylnortestosterone (17 β -hydroxy-17 α -methylestra-4,9,11-trien-3-one); methylnortestosterone (17 β -hydroxy-17 α -androstane); mibolerone; noradrostenedione (estr-4-ene-3,17-dione) norboletone norclostebol norethandrolone; oxandrolone; oxymesterone; oxymetholone; prostano

b. Endogenous** AAS when administered exogenously :

Androstenediol (androst-5-ene- 3β ,17 β -diol); androstenedione, (androst-4-ene-3,17-dione); dihydrotestosterone; (17 β -hydroxy-5 α -androstan-3-one); prasterone (dehydroepiandrosterone,DHEA,3 β -hydroxyandrost-5-en-17-one) testosterone; and their metabolites and isomers, including but not limited to:

5α-androstane-3α-17α-diol; 5α-androstane-3α-17β-diol; 5α-androstane-3β-17α-diol; 5α-androstane-3β-17β-diol; 5βandrostane-3α-17β-diol; androst-4-ene-3α,17α-diol; androst-4-ene-3α,17β-diol; androst-4-ene-3β,17α-diol; androst-5-ene-3α,17α-diol; androst-5-ene-3α,17β-diol; androst-5-ene-3β,17β-diol; 4-androstendiol (androst-4-ene-3β,17β-diol); 5-androstenedione (androst-5-ene-3, 17-dione); androsterone (3β-hydroxy-5α-androstan-17-one); epidihydrotestrosterone; epitestostereone; etiocholanolone; 7α - hydorxy-DHEA; 7β- hyroxy-DHEA; 7-keto-DHEA; 19norandrosterone; 19-noretiocholanolone.

2. OTHER ANABOLIC AGENTS

Including, but not limited to:

Clenbuterol, selective and rogen receptor modulators (SARMs; e.g. and arine and ostarine), tibolone, zeranol and zilpaterol.

For purposes of this section:

* "exogenous" refers to a substance which is not ordinarily produced by the body naturally.

** "endogenous" refers to a substance which is ordinarily produced by the body naturally.

S2. PEPTIDE HORMONES, GROWTH FACTORS, RELATED SUBSTANCES AND MIMETICS

The following substances, and other substances with similar chemical structure or similar biological effect(s), are prohibited:

- 1. Erythropoietin Receptor agonists:
 - 1.1 Erythropoiesis-Stimulating Agents (ESAs) including e.g. darbepoietin (dEPO); erythropoietius (EPO);EPO-Fc; EPO mimetic peptides (EMP), e.g. CNTO 530 and peginesatide; and methoxy polyethylene glycol-epoetin beta (CERA)
 - 1.2 Non erythropoietic EPO Receptor agonists, e.g. ARA 290, asialo EPO and carbamylated EPO;
- 2. Hypoxia inducible factor (HIF) stabilizers, e.g. cobalt and FG-4592; and HIF activators, e.g. argon, xenon;
- 3. Chorionic Gonadotrophin (CG) and Luteinizing Hormone (LH) and their releasing factors, e.g. buserelin, gonadorelin and triptorelin, in males;
- 4. Corticotrophins and their releasing factors, e.g. corticorelin;
- 5. Growth Hormone (GH) and its releasing factors including Growth Hormone Releasing Hormone (GHRH) and its analogues, e.g. CJC-1295, sermorelin and tesamorelin; Growth Hormone Secretagogues (GHS), e.g. ghrelin and ghrelin mimetics, e.g. anamorelin and ipamorelin; and GH Releasing Peptides (GHRPs) e.g. alexamorelin, GHRP 6, hexarelin and pralmorelin (GHRP 2).

Additional prohibited growth factors:

Fibroblast Growth Factors (FGFs); **Hepatocyte Growth Factor** (HGF); **Insulin-like Growth Factor - 1** (IGF-1) and its **analogues; Mechano Growth Factors** (MGFs); **Platelet-Derived Growth Factor** (PDGF); **Vascular-Endothelial Growth Factor** (VEGF) and any other growth factor affecting muscle, tendon or ligament protein synthesis/ degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching.

S3. BETA - 2AGONISTS

All beta - 2 agonists, including all optical isomers, e.g. d - and l- where relevant, are prohibited.

Except:

- * Inhaled salbutamol (maximum 1600 micrograms over 24 hours)
- * Inhaled formoterol (maximum delivered dose 54 micrograms over 24 hours); and
- * Inhaled salmeterol in accordance with the manufacturers' recommended therapeutic regimen.

The presence in urine of salbutamol in excess of 1000 ng/ml- or formoterol in excess of 40ng/ml- is presumed not to be an intended therapeutic use of the substance and will be considered as an *Adverse Analytical Finding (AAF)* unless the *Athlete* proves, through a controlled pharmacokinetic study, that the abnormal result was the consequence of the use of the therapeutic inhaled dose up to the maximum indicated above.

S4. HORMONE AND METABOLIC MODULATORS

The following hormones and metabolic modulators are prohibited:

- 1. Aromatase inhibitors including, but not limited to: aminoglutethimide; anastrozole; androsta 1,4,6-triene-3, 17-dione (androstatrienedione); 4- androstene-3,6,17 trione (6-oxo); exemestane; formestane; letrozole and testolactone.
- 2. Selective estrogen receptor modulators (SERMs) including, but not limited to : raloxifene; tamoxifen and to emifene.
- 3. Other anti-estrogenic substances including, but not limited to: clomiphene; cyclofenil and fulvestrant.
- 4. Agents modifying myostatin function (s) including, but not limited, to : myostatin inhibitors.
- 5. Metabolic modulators:
 - 5.1 Activators of the AMP-activated protein kinase (AMPK), *e.g.* AICAR; and Peroxisome Proliferator Activated Receptor∂ (PPAR∂) agonists, *e.g.* GW 1516;
 - 5.2 Insulins;
 - 5.3 Trimetazidine;

S5. DIURETICS AND MASKING AGENTS

The following **diuretics**, and **masking agents** are prohibited, as are other substances with a similar chemical structure or similar biological effect (s).

Including, but not limited to:

- □ Desmopressin; probenecid; plasma expanders, *e.g.* glycerol and intravenous administration of albumin, dextran, hydroxyethyl starch and mannitol.
- □ Acetazolamide; amiloride; bumetanide; canrenone; chlortalidone; etacrynic acid; furosemide; indapamide; metolazone; spironolactone; thiazides, *e.g.* bendroflumethiazide, chlorothiazide and hydrochlorothiazide; triamterene and vaptans, *e.g.* tolvaptan.

Excpet:

- □ Drospirenone; pamabrom; and topical dorzolamide and brinzolamide.
- □ Local administration of felypressin in dental anaesthesia.

The detection in an **Athlete's Sample** at all times or **In -Competition**, as applicable, of any quantity of the following substances subject to threshold limits: formoterol, salbutamol, cathine, ephedrine, methylephedrine and pseudoephedrine, in conjunction with a diuretic or masking agent, will be considered as an *Adverse Analytical Finding* unless the *Athlete* has an approved **TUE** for that substance in addition to the one granted for the diuretic or masking agent.

PROHIBITED METHODS

M1. MANIPULATION OF BLOOD AND BLOOD COMPONENTS

The following are prohibited:

- 1. The administration or reintroduction of any quantity of autologous, allogenic (homologous) or heterologous blood, or red blood cell products of any origin into the circulatory system.
- Artificially enhancing the uptake, transport or delivery of oxygen. Including, but not limited to: Perfluorochemicals; efaproxiral (RSR 13) and modified haemoglobin products, *e.g.* haemoglobin-based blood substitutes and microencapsulated haemoglobin products, excluding supplemental oxygen.
- 3. Any form of intravascular manipulation of the blood or blood components by physical or chemical means.

M2. CHEMICAL AND PHYSICAL MANIPULATION

The following are prohibited:

- Tampering, or Attempting to Tamper, to alter the integrity and validity of Samples collected during Doping Control. Including, but not limited to: Urine substitution and/or adulteration, *e.g.* proteases.
- 2. Intravenous infusions and /or injections of more than 50ml per 6 hour period except for those legitimately received in the course of hospital admissions, surgical procedures or clinical investigations.

M3. GENE DOPING

The following with the potential to enhance sport performance, are prohibited:

- 1. The transfer of ploymers of nucleic acids or nucleic acid analogues;
- 2. The use of normal or genetically modified cells.

SUBSTANCES AND METHODS PROHIBITED IN-COMPETITION

In addition to the categories SO to S5 and M1 to M3 defined above, the following categories are prohibited in - Competition:

PROHIBITED SUBSTANCES

S6. STIMULANTS

All stimulants, including all optical isomers, e.g. d- and 1- where relevant, are prohibited.

Stimulants include:

(a) Non-Specified Stimulants:

6A I කොටස : (I) ඡෙදය - ශී ලංකා පුජාතාන්තික සමාජවාදී ජනරජයේ අති විශෙෂ ගැසට් පතුය - 2015.05.05 Part I : Sec. (I) - GAZETTE EXTRAORDINARY OF THE DEMOCRATIC SOCIALIST REPUBLIC OF SRI LANKA - 05.05.2015

Adrafinil; amfepramone; amfetamine; amfetaminil; amiphenazole; benfluorex; benzylpiperazine; bromantan; clobenzorex; cocaine; cropropamide; crotetamide; fencamine; fenetylline; fenfluramine; fenproporex; fonturacetam [4- phenylpiracetam (carphedon)]; furfenorex; mefenorex; mephentermine; mesocarb; metamfetamine (d-) p- methylamphetamine; modafinil; norfenfluramine; phendimetrazine; phentermine; prenylamine and prolintane.

A stimulant not expressly listed in this section is specified substance.

b. Specified Stimulants.

Including, but not limited to:

Benzfetamine; cathine**; cathinone and its analogues, e.g. mephedrone, methedrone, and a- pyrrolidinovalerophenone; dimethylamphetamine; ephedrine ***; epinephrine**** (adrenaline); etamivan; etilamfetamine; etilefrine; famprofazone; fenbutrazate; fencamfamin; heptaminol; hydroxyamfetamine (parahydroxyamphetamime); isometheptene; levmetamfetamine; meclofenoxate; methylenedioxymethamphetamine; methylephedrine***; methylhexaneamine; (dimethylpentylamine); methylphenidate; nikethamide, norfenefrine; octopamine; oxilofrine (methylsynephrine) pemoline; penterazol; phenethylamine and its derivatives; phenmetrazine; phenpromethamine; propylhexedrine; pseudoephedrine****; selegiline; sibutramine; strychnine; tenamfetamine (methylenedioxyamphetamine), tuaminoheptane; and other substances with a similar chemical structure or similar biological effect(s).

Except:

Imidazole derivatives for topical/ophthalmic use and those stimulats included in the 2015 monitoring Program*.

- * Bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradrol, and synephrine; These substances are included in the 2015 monitoring Program, and are not considered *Prohibited Substances*.
- ** Cathine: Prohibited when its concentration in urine is greater than 5 micrograms per milliliter.
- *** Ephedrine and methylephedrine: Prohibited when the concentration of either in urine is greater than 10 micrograms per milliliter.
- **** Epinephrine (adrenaline): Not prohibited in local administration, e.g. nasal, ophthalmologic, or co-administration with local anaesthetic agents.
- ***** Pseudoephedrine: Prohibited when its concentration in urine is greater than 150 micrograms per milliliter.

S7. NARCOTICS

Prohibited:

Buprenorphine; dextromoramide; diamorphine (heroin); fentanyl and its derivatives; hydromorphone; methadone; morphine; oxycodone; oxymorphone; pentazocine and pethidine.

S8. CANNABINOIDS

Prohibited:

- Natural, e.g. cannabis, hashish and marijuana, or synthetic
- 9- tetrahydrocannabinol (THC).
 Cannabimimetics, e.g. "Spice", JWH-018, JWH-073, HU-210.

S9. GLUCOCORTICOIDS

All glucocorticoids are prohibited when administred by oral, intravenous, intramuscular or rectal routs.

SUBSTANCES PROHIBITED IN-PARTICULAR SPORTS

P1. ALCOHOL

Alcohol (**ethanol**) is prohibited *In-Competition* only, in the following sports, Detection will be conducted by analysis of breath and /or blood. The doping violation threshold is equivalent to a blood alcohol concentration of 0.10g/L.

- □ Air Sports (FAI)
- □ Archery (WA)
- □ Automobile (FIA)

Motorcycling (FIM) Dewerbacting (UIM)

D Powerboating (UIM)

P2. BETA-BLOCKERS

Beta-blockers are prohibited *In-Competition* only, in the following sports, and also prohibited *Out-of-Competition* where indicated.

- □ Archery (WA)*
- □ Automobile (FIA)
- Billiards (all disciplines) (WCBS)
- Darts (WDF)
- □ Golf(IGF)
- □ Shooting (ISSF, IPC)*
- Skiing/Snowboarding (FIS) in ski Jumping, Freestyle aerials/halfpipe and snowboard halfpipe/big air.
- Underwater sports (CMAS) in constant-weight apnoea with or without fins, dynamic apnoea with and without fins, free immersion apnoea, Jump Blue apnoea, spearfishing, static apnoea, target shooting and variable weight apnoea.
- * Also proibited Out-of-Competition

Including, but not limited to :

Acebutolol; alprenolol; atenolol; betaxolol; bisoprolol; bunolol; carteolol; carvedilol; celiprolol; esmolol; labetalol; levobunolol; metipranolol; metoprolol; nadolol; oxprenolol; pindolol; propranolol; sotalol and timolol.

WORLD ANTI-DOPING AGENCY

THE 2015 MONITORING PROGRAM*

The following substances are placed on the 2015 Monitoring Program:

1.	Stimulants:	In-Competition only: Bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine,
		Pipradrol and synephrine.
2.	Narcotics:	In-Competition only: Hydrocodone, mitragynine, morphine/codeine ratio, tapentadol and
		tramadol
3.	Glucocorticoids:	In-Competition (by routes of administration other than oral, intravenous, intramuscular or
		rectal) and out-of-Competition (all routes of administration)
4.	Telmisartan:	In-and out -of -Competition
5.	Meldonium:	In-and out- of -Competition
		-

* The world Anti-Doping Code (Article 4.5) states : "WADA in consultation with Signatories and governments, shall establish a monitoring program regarding substances which are not on the Prohibited List, but which WADA wishes to monitor in order to detect patterns of misuse in sport."

05-451